Natera announces results of Signatera study

Natera (NTRA) announced the results of a study led by Stanford University School of Medicine for the evaluation of Signatera, Natera’s personalized molecular residual disease test, in patients with soft tissue and bone sarcomas. Results of the study were presented at the 2025 Society of Surgical Oncology annual meeting in March. With evaluation of approximately 200 patients and more than 2,100 plasma samples across multiple distinct subtypes, this is the largest sarcoma cohort to date using personalized circulating-tumor DNA monitoring. The study assessed the correlation of Signatera results with imaging, stratified by sarcoma subtype, and followed patients through treatment, disease progression, and surveillance. The results demonstrated test performance, with overall sensitivity to recurrence of 89% and specificity of 100%. In leiomyosarcoma, the most common subtype in the cohort, sensitivity was 93%, with specificity of 100%. For leiomyosarcoma patients who experienced progression, ctDNA kinetics during subsequent therapy were highly correlated with treatment response. To build on these findings, the team intends to launch a prospective study to further demonstrate Signatera’s clinical utility and explore its role in informing treatment decisions and improving future sarcoma care.